These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2747 related articles for article (PubMed ID: 29262275)

  • 1. Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
    Yarchoan M; Hopkins A; Jaffee EM
    N Engl J Med; 2017 Dec; 377(25):2500-2501. PubMed ID: 29262275
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.
    Qin BD; Jiao XD; Zang YS
    Med Hypotheses; 2018 Jul; 116():111-113. PubMed ID: 29857892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
    Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
    Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
    Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
    Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDL-1/PD1 inhibitors: antibody or antinobody?
    Aoun F; Rassy EE; Assi T; Kattan J
    Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
    [No Abstract]   [Full Text] [Related]  

  • 6. Biomarkers of response to PD-1/PD-L1 inhibition.
    Maleki Vareki S; Garrigós C; Duran I
    Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
    Novotny JF; Cogswell J; Inzunza H; Harbison C; Horak C; Averbuch S
    Ann Oncol; 2016 Oct; 27(10):1966-9. PubMed ID: 27502705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
    Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G
    Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724
    [No Abstract]   [Full Text] [Related]  

  • 10. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468
    [No Abstract]   [Full Text] [Related]  

  • 11. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.
    Manogue C; Cotogno P; Ledet E; Lewis B; Wyatt AW; Sartor O
    Oncologist; 2019 Apr; 24(4):444-448. PubMed ID: 30541755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
    Brower V
    Lancet Oncol; 2016 Dec; 17(12):e527. PubMed ID: 27866860
    [No Abstract]   [Full Text] [Related]  

  • 15. [The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].
    Xu Y; Bai L
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):799-803. PubMed ID: 30347553
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
    Nowicki TS; Hu-Lieskovan S; Ribas A
    Cancer J; 2018; 24(1):47-53. PubMed ID: 29360728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation predictive biomarkers for immune checkpoint inhibition.
    Khagi Y; Kurzrock R; Patel SP
    Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.
    Colli LM; Machiela MJ; Myers TA; Jessop L; Yu K; Chanock SJ
    Cancer Res; 2016 Jul; 76(13):3767-72. PubMed ID: 27197178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 138.